Moreover, published clinical trials showed that intravenous α1AT or inhibition of cathepsin C, a dipeptidyl peptidase required for the maturation of NSPs into active enzymes, did not improve the clinical course of hospitalized COVID-19 patients (56, 57). The gene discussed is CTSC; the disease is COVID-19.